Cargando…

Treatment According to Molecular Profiling in Relapsed/Refractory Cancer Patients: A Review Focusing on Latest Profiling Studies

In this review we aim to summarize studies investigating the impact of a molecular profiling (MP)-guided treatment approach in heavily pretreated cancer patients. In summary, many independent single- and multicenter studies showed a significant benefit of MP-guided treatment regarding response rates...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zimmer, Kai, Kocher, Florian, Spizzo, Gilbert, Salem, Mohamed, Gastl, Guenther, Seeber, Andreas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Research Network of Computational and Structural Biotechnology 2019
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6453774/ https://www.ncbi.nlm.nih.gov/pubmed/31007870 http://dx.doi.org/10.1016/j.csbj.2019.03.012

Ejemplares similares

Treatment of patients with refractory metastatic cancer according to molecular profiling on tumor tissue in the clinical routine: an interim-analysis of the ONCO-T-PROFILE project
por: Seeber, Andreas, et al.
Publicado: (2016)

Cost-comparison analysis of a multiplatform tumour profiling service to guide advanced cancer treatment
por: Spizzo, Gilbert, et al.
Publicado: (2019)

Expression of EpCAM(MF) and EpCAM(MT) variants in human carcinomas
por: Fong, Dominic, et al.
Publicado: (2014)

Soluble EpCAM levels in ascites correlate with positive cytology and neutralize catumaxomab activity in vitro
por: Seeber, Andreas, et al.
Publicado: (2015)

Phenotype-dependent effects of EpCAM expression on growth and invasion of human breast cancer cell lines
por: Martowicz, Agnieszka, et al.
Publicado: (2012)

Detection of soluble EpCAM (sEpCAM) in malignant ascites predicts poor overall survival in patients treated with catumaxomab
por: Seeber, Andreas, et al.
Publicado: (2015)

Molecular profile of BRCA-mutated biliary tract cancers
por: Spizzo, Gilbert, et al.
Publicado: (2020)

Targeting BRCA and DNA Damage Repair Genes in GI Cancers: Pathophysiology and Clinical Perspectives
por: Zimmer, Kai, et al.
Publicado: (2021)

EpCAM overexpression prolongs proliferative capacity of primary human breast epithelial cells and supports hyperplastic growth
por: Martowicz, Agnieszka, et al.
Publicado: (2013)

Concise Review: Aggressive Colorectal Cancer: Role of Epithelial Cell Adhesion Molecule in Cancer Stem Cells and Epithelial‐to‐Mesenchymal Transition
por: Boesch, Maximilian, et al.
Publicado: (2018)

WRN-Mutated Colorectal Cancer Is Characterized by a Distinct Genetic Phenotype
por: Zimmer, Kai, et al.
Publicado: (2020)

Profile of belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma
por: Bodiford, Andrew, et al.
Publicado: (2014)

Effects of EpCAM overexpression on human breast cancer cell lines
por: Gostner, Johanna M, et al.
Publicado: (2011)

EpCAM expression in primary tumour tissues and metastases: an immunohistochemical analysis
por: Spizzo, Gilbert, et al.
Publicado: (2011)

The mutational profile of immune surveillance genes in diagnostic and refractory/relapsed DLBCLs
por: Nesic, Marijana, et al.
Publicado: (2021)

Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma
por: Mu, Song, et al.
Publicado: (2015)

Impact and Novel Perspective of Immune Checkpoint Inhibitors in Patients with Early and Intermediate Stage HCC
por: Marzi, Luca, et al.
Publicado: (2022)

Profile of blinatumomab and its potential in the treatment of relapsed/refractory acute lymphoblastic leukemia
por: Ribera, Josep-Maria, et al.
Publicado: (2015)

Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib
por: Denlinger, Nathan M, et al.
Publicado: (2018)

Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma
por: Seeber, Andreas, et al.
Publicado: (2020)

Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2022 ASH annual meeting
por: Gong, Xubo, et al.
Publicado: (2023)

High indoleamine-2,3-dioxygenase 1 (IDO) activity is linked to primary resistance to immunotherapy in non-small cell lung cancer (NSCLC)
por: Kocher, Florian, et al.
Publicado: (2021)

Profile of venetoclax and its potential in the context of treatment of relapsed or refractory chronic lymphocytic leukemia
por: Huber, Henriette, et al.
Publicado: (2017)

Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
por: Lee, Boram, et al.
Publicado: (2021)

Emerging Pharmacotherapy for Relapsed or Refractory Hodgkin’s Lymphoma: Focus on Brentuximab Vedotin
por: Furtado, Michelle, et al.
Publicado: (2012)

Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib
por: Nooka, Ajay, et al.
Publicado: (2013)

Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib
por: Smith, Catherine C., et al.
Publicado: (2022)

Immunotherapies targeting GPRC5D in relapsed or refractory multiple myeloma: latest updates from 2022 ASH Annual Meeting
por: Xia, Jieyun, et al.
Publicado: (2023)

BCMA-targeted CAR-T cell therapies in relapsed and/or refractory multiple myeloma: latest updates from 2023 ASCO Annual Meeting
por: Wu, James F., et al.
Publicado: (2023)

PB2263: TOXICITY PROFILE OF SALVAGE CHEMOTHERAPY REGIMENS IN PATIENTS WITH RELAPSED/ REFRACTORY HODGKIN LYMPHOMA.
por: Zahra, Kmira, et al.
Publicado: (2023)

Targeted Therapy for Relapsed/Refractory Follicular Lymphoma: Focus on Clinical Utility of Tazemetostat
por: Raychaudhuri, Ruben, et al.
Publicado: (2022)

Targeted Treatment of Relapsed or Refractory Follicular Lymphoma: Focus on the Therapeutic Potential of Mosunetuzumab
por: Lopedote, Paolo, et al.
Publicado: (2023)

High IDO‐1 expression in tumor endothelial cells is associated with response to immunotherapy in metastatic renal cell carcinoma
por: Seeber, Andreas, et al.
Publicado: (2018)

MicroRNA Profile Alterations in Parathyroid Carcinoma: Latest Updates and Perspectives
por: Wielogórska, Marta, et al.
Publicado: (2022)

Laboratory Diagnosis of Tick-Borne African Relapsing Fevers: Latest Developments
por: Fotso Fotso, Aurélien, et al.
Publicado: (2015)

Comparative proteomic profiling of refractory/relapsed multiple myeloma reveals biomarkers involved in resistance to bortezomib-based therapy
por: Dytfeld, Dominik, et al.
Publicado: (2016)

Risk profiling of patients with relapsed/refractory diffuse large B-cell lymphoma by measuring circulating tumor DNA
por: Herrera, Alex F., et al.
Publicado: (2022)

Safety Profile of Ixazomib in Patients with Relapsed/Refractory Multiple Myeloma in Japan: An All-case Post-marketing Surveillance
por: Kakimoto, Yoshihide, et al.
Publicado: (2021)

The Prognostic Impact of Comorbidities in Patients with De-Novo Diffuse Large B-Cell Lymphoma Treated with R-CHOP Immunochemotherapy in Curative Intent
por: Kocher, Florian, et al.
Publicado: (2020)

Latest Review Papers in Molecular Microbiology
por: Burkovski, Andreas
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_emuo0t4cruo5t569v0pk2mt79c